Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1080/14712598.2021.1847269

http://scihub22266oqcxt.onion/10.1080/14712598.2021.1847269
suck pdf from google scholar
33161757!ä!33161757

suck abstract from ncbi

pmid33161757      Expert+Opin+Biol+Ther 2021 ; 21 (5): 615-626
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • A comprehensive review on sarilumab in COVID-19 #MMPMID33161757
  • Khiali S; Rezagholizadeh A; Entezari-Maleki T
  • Expert Opin Biol Ther 2021[May]; 21 (5): 615-626 PMID33161757show ga
  • Introduction: The coronavirus disease 2019 (COVID-19) pandemic, caused by a newly discovered coronavirus (severe acute respiratory syndrome coronavirus 2, or SARS-CoV-2), continues to spread all around the world. Despite the emergency of COVID-19 worldwide, remdesivir is the only treatment that has been recently approved to treat the diseases, and other effective therapies are still lacking. SARS-CoV-2 may cause severe illness in 20% of patients. Based on available data, there is an association between interleukin-6 (IL-6) and severe COVID-19. Sarilumab is a fully human immunoglobulin G1 monoclonal antibody binding to both membrane-bound and soluble IL-6 receptors with high affinity and has been considered for off-label use in the treatment of COVID-19.Areas covered: The present article reviews recently published literature focusing on the pathophysiology of COVID-19 induced cytokine storm, the potential therapeutic role, and important clinical issues of sarilumab in the treatment of COVID-19 patients.Expert opinion: The off-label treatment administration is unavoidable in the critical situation of the COVID-19 pandemic. Further efforts should be directed to determine mechanisms of SARS-CoV-2 induced immune dysregulation as well as indications of sarilumab in the patients with COVID-19 to minimize concerns regarding its off-label administration.
  • |*COVID-19 Drug Treatment[MESH]
  • |Adenosine Monophosphate/analogs & derivatives/metabolism/therapeutic use[MESH]
  • |Alanine/analogs & derivatives/metabolism/therapeutic use[MESH]
  • |Animals[MESH]
  • |Antibodies, Monoclonal, Humanized/metabolism/pharmacology/*therapeutic use[MESH]
  • |Antiviral Agents/metabolism/pharmacology/therapeutic use[MESH]
  • |COVID-19/epidemiology/metabolism[MESH]
  • |Cytokine Release Syndrome/*drug therapy/epidemiology/metabolism[MESH]
  • |Humans[MESH]
  • |Pandemics[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box